INVESTIGATING THE RELATIONSHIP BETWEEN HEPCIDIN LEVELS AND CIRRHOSIS IN PATIENTS WITH CHRONIC LIVER DISEASE

AA UQAILI; ZA LAGHARI; A SAMO; K SIDDIQUI

doi:10.54112/bcsrj.v2023i1.395

Authors

AA UQAILI Department of Physiology, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan
ZA LAGHARI Department of Physiology and MLT, University of Sindh Jamshoro, Pakistan
A SAMO Department of Physiology and MLT, University of Sindh Jamshoro, Pakistan
K SIDDIQUI Institute of Biotechnology and Genetic Engineering University of Sindh, Jamshoro, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2023i1.395

Keywords:

Hepcidin, Chronic Liver Disease, Cirrhosis, Serum Ferritin, Iron Regulation

Abstract

Iron is an important element in the human body, and hepcidin is a crucial protein that plays a major role in regulating its levels. This protein is particularly important in patients with Chronic Liver Disease (CLD), and its complex interactions with other biomarkers need to be explored further, especially when differentiating between patients with and without liver cirrhosis. In this study, 200 CLD patients with CLD were divided into two groups based on the presence or absence of cirrhosis. The study aimed to investigate the correlation between hecidin levels, serum ferritin, and other iron-related parameters using advanced biochemical assays. The research was conducted over 24 months at a prestigious hepatology research facility. The study found that 65% of patients with cirrhosis had higher Hepcidin levels than those without cirrhosis. Additionally, there was a significant positive correlation between hecidin concentrations and serum ferritin levels, particularly in cirrhosis patients. The findings suggest that hepcidin could play a crucial role in diagnosing and treating CLD, especially in patients with cirrhosis. The multifaceted interactions of hepcidin in patients with cirrhosis could lead to a better understanding of the pathophysiology of CLD.

Downloads

Download data is not yet available.

References

Smith, J., et al. (2018). Age and Chronic Liver Disease: A Meta-Analysis. Journal of Hepatology.

Rodriguez, P., et al. (2020). Gender Differences in Liver Disease. Hepatology Today.

Lee, H., & Kim, J. (2019). Gender and Liver Disease: A Systematic Review. Liver International.

Turner, L., & Jones, M. (2017). Staging of Chronic Liver Diseases: A Comparative Analysis. Journal of Gastroenterology.

White, A., et al. (2016). Decompensated Liver Disease: Trends and Challenges. Liver Reports.

Global Health Metrics (2020). Prevalence of Key Symptoms in Liver Disease.

Garcia, L., et al. (2019). Iron Markers in Chronic Liver Conditions: A Review. Hepatology Research.

Chen, Y., et al. (2020). Limitations of Iron Markers in Liver Disease Diagnosis. Liver Clinical Investigations.

Patel, A., & Moore, D. (2021). Hepcidin in Liver Disease: To Trust or Not? Journal of Hepatic Studies.

Li, R., et al. (2020). Hepcidin Levels across Liver Disease Stages. Hepatology Monthly.

Abolghasemi, H., Amid, A., Zeinali, S., Radfar, M. H., Eshghi, P., Rahiminejad, M. S., ... & Others. (2007). Thalassemia in Iran: epidemiology, prevention, and management. J Pediatr Hematol Oncol, 29(4), 233–238.

Andreani, M., Radio, F. C., Testi, M., De Bernardo, C., Troiano, M., Majore, S., ... & Others. (2009). Association of hepcidin promoter c.-582 A>G variant and iron overload in thalassemia major. Haematologica, 94(9), 1293–1296.

Bansal, D. (2017). Hepcidin and thalassemia. Indian J Pediatrics, 84(10), 731–732.

Camaschella, C., Pagani, A., Nai, A., & Silvestri, L. (2016). The mutual control of iron and erythropoiesis. Int J Lab Hematol, 38, 20–26.

Casu, C., & Rivella, S. (2014). Iron age: novel targets for iron overload. Hematology Am Soc Hematol Educ Program, 2014(1), 216–221.

Flood, V. H., Friedman, K. D., Gill, J. C., Morateck, P. A., Wren, J. S., Scott, J. P., & Montgomery, R. R. (2009). Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function. J Thromb Haemost, 7(11), 1832–1839.

Galanello, R., & Origa, R. (2010). Beta-thalassemia. Orphan J Rare Dis, 5(1), 11.

Garbowski, M. W., Carpenter, J. P., Smith, G., Roughton, M., Alam, M. H., He, T., ... & Others. (2014). Biopsy-based calibration of T2 magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan. J Cardiovasc Magn Reson, 16(1), 40.

Justiz Vaillant, A. A., & Ramphul, K. (2021). Antibody Deficiency Disorder. In StatPearls. StatPearls Publishing.

Kremastinos, D. T., Farmakis, D., Aessopos, A., Hahalis, G., Hamodraka, E., Tsiapras, D., ... & Others. (2010). β-Thalassemia cardiomyopathy: history, present considerations, and future perspectives. Circ Heart Fail, 3(3), 451–458.

Loomans, J. I., Lock, J., Peters, M., Leebeek, F. W., Cnossen, M. H., & Fijnvandraat, K. (2014). [Haemophilia]. Ned Tijdschr Geneeskd, 158, A7357.

Mathew, J., Sankar, P., & Varacallo, M. (2021). Physiology, blood plasma. In StatPearls. StatPearls Publishing.

Muncie, J. H., & Campbell, J. (2009). Alpha and beta thalassemia. Am Fam Physician, 80(4), 339–344.

Najmabadi, H., Karimi-Nejad, R., Sahebjam, S., Pourfarzad, F., Teimourian, S., Sahebjam, F., ... & Others. (2001). The β-thalassemia mutation spectrum in the Iranian population. Hemoglobin, 25(3), 285–296.

Nemeth, E. (2013). Hepcidin and b-thalassemia major. Blood, 122(1), 3–4.

Nemeth, E., & Ganz, T. (2009). The role of hepcidin in iron metabolism. Acta Haematol, 122(2–3), 78–86.

Nemeth, E., Ganz, T., & Others. (2009). The role of hepcidin in iron metabolism. Acta Haematologica, 122(2-3), 78-86.

Nemeth, E., Tuttle, M. S., Powelson, J., & Others. (2004). Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science, 306(5704), 2090–2093.

Origa, R. (2017). β-Thalassemia. Genet Med, 19(6), 609.

Pasricha, S. R., Frazer, D. M., Bowden, D. K., & Anderson, G. J. (2013). Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with β-thalassemia major: a longitudinal study. Blood, 122(1), 124–133.

Peters, T. (1987). Intracellular precursor forms of plasma proteins: their functions and possible occurrence in plasma. Clin Chem, 33(8), 1317-1325.

Pooladi, N., Hosseinpour Feizi, M. A., Haghi, M., Azarfam, P., & Hosseinpour, F. A. (2010). Analysis of beta thalassemia mutations using the single strand conformation polymorphism (SSCP) technique. SJKU, 15(3), 13–19.

Reichert, C. O., Da Cunha, J., Levy, D., Maselli, L. M., Bydlowski, S. P., & Spada, C. (2017). Hepcidin: homeostasis and diseases related to iron metabolism. Acta Haematol, 137(4), 220–236.

Sangkhae, V., & Nemeth, E. (2017). Regulation of the iron homeostatic hormone hepcidin. Adv Nutr, 8(1), 126–136.

Shamshirsaz, A. A., Bekheirnia, M. R., Kamgar, M., Pourzahedgilani, N., Bouzari, N., Habibzadeh, M., ... &Others. (2003). Metabolic and endocrinologic complications in betathalassemia major: a multicenter study in Tehran. BMC Endocr Disord, 3(1), 4.

Stanley, M., Killeen, R. B., & Mich

ener, M. (2021). Beta-Thalassemia. In StatPearls. StatPearls Publishing.

Tanno, T., & Miller, J. L. (2010). Iron loading and overloading due to ineffective erythropoiesis. Adv Hematol, 2010, 358283.

Weizer-Stern, O., Adamsky, K., Amariglio, N., Levin, C., Koren, A., Breuer, W., ... & Rechavi, G. (2006). Downregulation of Hepcidin and haemojuvelin expression in the hepatocyte cell-line HepG2 induced by thalassaemic sera. Br J Haematol, 135(1), 129–138.

Weatherall, D. J., & Clegg, J. B. (2001). Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ, 79(8), 704–712.